|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/14/22 ENDRA Life Sciences Inc. 10-Q 9/30/22 52:3.2M Blueprint/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 753K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
10: R1 Cover HTML 71K
11: R2 Condensed Consolidated Balance Sheets HTML 107K
12: R3 Condensed Consolidated Balance Sheets HTML 36K
(Parenthetical)
13: R4 Condensed Consolidated Statements of Operations HTML 68K
(Unaudited)
14: R5 Condensed Consolidated Statements of Stockholders HTML 78K
Equity (Unaudited)
15: R6 Condensed Consolidated Statements of Cash Flows HTML 91K
(Unaudited)
16: R7 Nature of the Business HTML 18K
17: R8 Summary of Significant Accounting Policies HTML 48K
18: R9 Inventory HTML 18K
19: R10 Fixed Assets HTML 24K
20: R11 Accounts Payable and Accrued Liabilities HTML 25K
21: R12 Bank Loans HTML 19K
22: R13 Capital Stock HTML 28K
23: R14 Common Stock Options HTML 30K
24: R15 Common Stock Warrants HTML 29K
25: R16 Commitments and Contingencies HTML 35K
26: R17 Subsequent Events HTML 21K
27: R18 Summary of Significant Accounting Policies HTML 78K
(Policies)
28: R19 Summary of Significant Accounting Policies HTML 23K
(Tables)
29: R20 Fixed Assets (Tables) HTML 22K
30: R21 Accounts Payable and Accrued Liabilities (Tables) HTML 25K
31: R22 Common Stock Options (Tables) HTML 30K
32: R23 Common Stock Warrants (Tables) HTML 29K
33: R24 Commitments and Contingencies (Tables) HTML 24K
34: R25 Summary of Significant Accounting Policies HTML 22K
(Details)
35: R26 Summary of Significant Accounting Policies HTML 32K
(Details Narrative)
36: R27 Inventory (Details Narrative) HTML 17K
37: R28 Fixed Assets (Details) HTML 25K
38: R29 Fixed Assets (Details Narrative) HTML 17K
39: R30 Accounts Payable and Accrued Liabilities (Details) HTML 30K
40: R31 Bank Loans (Details Narrative) HTML 23K
41: R32 Capital Stock (Details Narrative) HTML 72K
42: R33 Common Stock Options (Details) HTML 54K
43: R34 Common Stock Options (Details Narrative) HTML 30K
44: R35 Common Stock Warrants (Details) HTML 40K
45: R36 Commitments and Contingencies (Details) HTML 34K
46: R37 Commitments and Contingencies (Details Narrative) HTML 50K
47: R38 Subsequent Event (Details Narrative) HTML 19K
50: XML IDEA XML File -- Filing Summary XML 91K
48: XML XBRL Instance -- ndra_10q_htm XML 653K
49: EXCEL IDEA Workbook of Financial Reports XLSX 82K
7: EX-101.CAL XBRL Calculations -- ndra-20220930_cal XML 97K
9: EX-101.DEF XBRL Definitions -- ndra-20220930_def XML 257K
6: EX-101.LAB XBRL Labels -- ndra-20220930_lab XML 606K
8: EX-101.PRE XBRL Presentations -- ndra-20220930_pre XML 452K
5: EX-101.SCH XBRL Schema -- ndra-20220930 XSD 125K
51: JSON XBRL Instance as JSON Data -- MetaLinks 231± 318K
52: ZIP XBRL Zipped Folder -- 0001654954-22-015303-xbrl Zip 140K
EXHIBIT 31.2
CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Irina Pestrikova, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q of ENDRA Life Sciences Inc.: |
|
|
|
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
|
|
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
|
|
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
|
| b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
|
| c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
|
|
| d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
|
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|
|
|
|
|
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
|
| ENDRA LIFE SCIENCES INC. |
| |
|
|
|
|
|
| Date: November 14, 2022 | By: | /s/ Irina Pestrikova |
|
|
|
|
| |
|
|
| Senior Director, Finance (Principal Financial and Accounting Officer) |
|
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/14/22 | 8-K | ||
| For Period end: | 9/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/27/22 ENDRA Life Sciences Inc. 8-K:3,5,9 9/27/22 13:184K Blueprint/FA 6/18/20 ENDRA Life Sciences Inc. 8-K:5,9 6/16/20 2:54K Blueprint/FA 12/26/19 ENDRA Life Sciences Inc. 8-K:1,3,5,912/19/19 4:390K Blueprint/FA 12/11/19 ENDRA Life Sciences Inc. 8-K:1,3,7,912/05/19 6:503K Blueprint/FA 5/12/17 ENDRA Life Sciences Inc. 8-K:5,9 5/08/17 6:209K Blueprint/FA 11/21/16 ENDRA Life Sciences Inc. S-1 11/18/16 29:4.1M Blueprint/FA |